A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Trial Profile

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Sitravatinib (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
  • Sponsors MethylGene; Mirati Therapeutics
  • Most Recent Events

    • 13 Nov 2017 According to a Mirati Therapeutics media release, phase Ib proof-of-concept data from this trial in genetically selected patients with NSCLC and other solid tumours expected by mid-2018.
    • 18 Oct 2017 Results assessing CBL mutations as potential mediators of EGFR-TKI resistance effectively treated with Sitravatinib (n=1), presented at the 18th World Conference on Lung Cancer
    • 14 Sep 2017 According to a Mirati Therapeutics media release, data from a single patient in this trial will be presented at the IASLC 18th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top